β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Animals
Antimetabolites, Antineoplastic
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Line, Tumor
Cisplatin
/ administration & dosage
Cohort Studies
Deoxycytidine
/ administration & dosage
Drug Resistance, Neoplasm
/ genetics
Female
Humans
Male
Mice
Mice, Nude
Phenotype
Prognosis
Stem Cells
/ drug effects
Transfection
Tumor Burden
/ drug effects
Urinary Bladder Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
beta-Arrestin 1
/ genetics
beta-Arrestin 2
/ genetics
Gemcitabine
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
10
10
2018
revised:
04
01
2019
accepted:
08
02
2019
pubmed:
23
2
2019
medline:
27
2
2020
entrez:
22
2
2019
Statut:
ppublish
Résumé
β-Arrestins are classic attenuators of G-protein-coupled receptor signaling. However, they have multiple roles in cellular physiology, including carcinogenesis. This work shows for the first time that β-arrestins have prognostic significance for predicting metastasis and response to chemotherapy in bladder cancer. β-Arrestin-1 (ARRB1) and β-arrestin-2 (ARRB2) mRNA levels were measured by quantitative RT-PCR in two clinical specimen cohorts (
Identifiants
pubmed: 30787175
pii: 1535-7163.MCT-18-1167
doi: 10.1158/1535-7163.MCT-18-1167
pmc: PMC6510267
mid: NIHMS1521941
doi:
Substances chimiques
ARRB1 protein, human
0
ARRB2 protein, human
0
Antimetabolites, Antineoplastic
0
beta-Arrestin 1
0
beta-Arrestin 2
0
Deoxycytidine
0W860991D6
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
801-811Subventions
Organisme : NCI NIH HHS
ID : F31 CA236437
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA156776
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227277
Pays : United States
Organisme : BLRD VA
ID : I01 BX003862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176691
Pays : United States
Organisme : BLRD VA
ID : I01 BX001517
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA123063
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072821
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Int J Cancer. 2002 Mar 10;98(2):297-309
pubmed: 11857423
Oncogene. 2012 Jan 19;31(3):282-92
pubmed: 21685944
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Cancer Res. 2012 Jul 1;72(13):3135-42
pubmed: 22532166
Curr Stem Cell Res Ther. 2014 Mar;9(2):89-101
pubmed: 24236543
Sci Rep. 2017 Jun 8;7(1):3058
pubmed: 28596572
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1492-7
pubmed: 16432186
Cancer. 2011 Mar 15;117(6):1197-209
pubmed: 20960509
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21
pubmed: 19666525
Annu Rev Physiol. 2007;69:483-510
pubmed: 17305471
Oncol Rep. 2014 Feb;31(2):727-36
pubmed: 24337040
Cancer Control. 2013 Jul;20(3):200-10
pubmed: 23811704
Nat Med. 2014 Jan;20(1):14-5
pubmed: 24398956
Cell Death Differ. 2016 Sep 1;23(9):1529-41
pubmed: 27128598
J Immunol. 2008 Apr 15;180(8):5699-706
pubmed: 18390755
Cell Death Dis. 2016 May 19;7:e2229
pubmed: 27195676
Mod Pathol. 2015 May;28(5):612-30
pubmed: 25412849
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Mol Cancer Res. 2016 May;14(5):493-503
pubmed: 26921391
Exp Hematol. 1996 Sep;24(11):1340-6
pubmed: 8862446
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Eur Urol. 2013 Jan;63(1):16-35
pubmed: 23083804
BMC Cancer. 2009 Feb 19;9:61
pubmed: 19228380
Nature. 2018 May;557(7705):381-386
pubmed: 29720660
J Cell Sci. 2007 Jan 15;120(Pt 2):213-8
pubmed: 17215450
Cancer Lett. 2015 Feb 1;357(1):170-178
pubmed: 25444908
Clin Cancer Res. 2017 Nov 1;23(21):6673-6685
pubmed: 28765327
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Int J Mol Sci. 2015 Dec 29;17(1):
pubmed: 26729098
Cancer Metastasis Rev. 2007 Mar;26(1):85-110
pubmed: 17345146
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2078-83
pubmed: 22308455
Nat Cell Biol. 2014 May;16(5):469-78
pubmed: 24747439
Cancer. 2015 Aug 1;121(15):2586-93
pubmed: 25872978
Exp Cell Res. 2017 Aug 1;357(1):51-58
pubmed: 28442265
Urol Oncol. 2015 May;33(5):204.e1-7
pubmed: 25814145
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Stem Cells. 2009 Jul;27(7):1487-95
pubmed: 19544456
Nat Rev Clin Oncol. 2017 Apr;14(4):221-234
pubmed: 27874062
Eur Urol. 2018 Feb;73(2):149-152
pubmed: 28917596
Nat Commun. 2015 Jun 16;6:7369
pubmed: 26077142
Oncotarget. 2014 Nov 15;5(21):10486-502
pubmed: 25401222
Anticancer Res. 1995 Jul-Aug;15(4):1191-8
pubmed: 7544562
Oncotarget. 2015 Nov 3;6(34):36185-201
pubmed: 26452033
J Vis Exp. 2011 Mar 13;(49):
pubmed: 21445039
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Gut. 2009 Jul;58(7):949-63
pubmed: 18829980
Cancer Res. 2011 May 1;71(9):3268-77
pubmed: 21398406
Arch Pathol Lab Med. 2012 Nov;136(11):1339-46
pubmed: 23106579